Antisense Oligonucleotides Restore Dysferlin Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating muscular dystrophies caused by dysferlin gene mutations, such as Miyoshi myopathy and limb girdle muscular dystrophy type 2B, are inadequate as they fail to effectively address the abnormal splicing of the DYSF gene, leading to premature stop codons and protein dysfunction.
Innovation Solution
The use of antisense nucleic acids, specifically oligonucleotides targeting the DYSF gene, to modulate splicing by preventing the inclusion of pseudoexons between exons 50 and 51, thereby restoring normal RNA expression and dysferlin protein levels, is employed. These oligonucleotides are delivered via viral vectors like rAAV to cells in vitro or in vivo, ensuring complementarity with specific sequences within the DYSF gene to alter splicing patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard exon sequencing methods are used to diagnose dysferlin gene mutations, then common mutations can be detected, but deep intronic mutations and abnormal splicing events remain undetected
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to pre-mRNA to modulate splicing and prevent pseudoexon inclusion. This intermediary approach allows detection and correction of deep intronic mutations that standard sequencing cannot identify, resolving the contradiction between detection precision and method coverage
2Reliability
If conventional treatment approaches are used for dysferlinopathy, then general symptomatic management is provided, but abnormal splicing and pseudoexon inclusion are not effectively addressed
Solution Approach 1:
The patent applies local quality by designing antisense oligonucleotides with specific sequences that target only the abnormal splicing sites containing pseudoexons. This localized intervention corrects specific splicing defects without affecting overall gene function, enabling precise treatment of dysferlinopathy while maintaining treatment flexibility for different mutation types
3Manufacturing precision
If antisense oligonucleotides are designed to target pseudoexon regions, then abnormal splicing can be corrected, but the complexity of identifying appropriate target sequences increases
Solution Approach 1:
The patent segments the complex splicing correction problem into manageable parts by dividing the antisense oligonucleotide into specific functional regions: a 5' region that binds to the pseudoexon, a central region that blocks splice site recognition, and a 3' region that ensures proper positioning. This segmentation simplifies the design process while maintaining high splicing correction accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively inhibits the inclusion of aberrant pseudoexons, leading to increased production of normal dysferlin mRNA and protein, thereby ameliorating muscular dystrophy symptoms by restoring functional dysferlin protein expression.
Implementation Method 1
antisense nucleic acid that targets a prem-RNA such that exons 50 and 51 of the pre-mRNA are spliced together without an intervening pseudoexon
Data Source
AI summary
The relates, in some aspects, to antisense oligonucleotide compositions and methods for modifying pre-mRNA splicing in a DYSF gene using the same. In some embodiments, the DYSF gene comprises a novel mutation that results in a pseudoexon between exons 50 and 51.